Another targeted therapeutic agent is brentuximab vedotin, which eliminates tumor cells by binding to CD30, a marker molecule abundantly expressed on the surface of anaplastic large-cell lymphoma cells, and subsequently releasing cytotoxic agents.58 Here, TNFRSF8 is linked to anaplastic large cell lymphoma.